Research programme: melanocyte stimulating hormone analogues - Melacure Therapeutics

Drug Profile

Research programme: melanocyte stimulating hormone analogues - Melacure Therapeutics

Alternative Names: Alpha-melanocyte stimulating hormone analogues - Melacure Therapeutics; Alpha-MSH analogues research programme - Melacure Therapeutics; Melanocyte stimulating hormone analogues research programme - Melacure Therapeutics; MS05; MS09; MSH analogues research programme - Melacure Therapeutics; Research programme: alpha-melanocyte stimulating hormone analogues - Melacure Therapeutics; Research programme: alpha-MSH analogues - Melacure Therapeutics; Research programme: MSH analogues - Melacure Therapeutics

Latest Information Update: 18 Aug 2003

Price : $50

At a glance

  • Originator Melacure Therapeutics (CEASED); University of Muenster; Uppsala University
  • Class
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 18 Aug 2003 Discontinued - Preclinical for Inflammation in Sweden (unspecified route)
  • 07 Nov 2002 No development reported - Preclinical for Inflammation in Sweden (unspecified route)
  • 26 Jul 2000 Preclinical development for Inflammation in Sweden (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top